YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
November 11, 2025 at 8:04 PM
YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).
ja.ma/4nOE3lp
ja.ma/4nOE3lp
November 11, 2025 at 1:30 PM
Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).
ja.ma/4nOE3lp
ja.ma/4nOE3lp
#MedSky American College of Cardiology says chronic, low-grade inflammation also directly linked to CVD. High levels of inflammation are linked to elevated heart disease risk, even if cholesterol looks fine. Key marker is high-sensitivity C-reactive protein. Time to track hsCRP alongside LDL.
Heart Disease Is an Inflammation Problem, According to New Scientific Statement | Super Age
New scientific statement links inflammation and heart disease. Here’s the blood test that detects it, and lifestyle changes for your heart.
tinyurl.com
October 5, 2025 at 2:15 PM
#MedSky American College of Cardiology says chronic, low-grade inflammation also directly linked to CVD. High levels of inflammation are linked to elevated heart disease risk, even if cholesterol looks fine. Key marker is high-sensitivity C-reactive protein. Time to track hsCRP alongside LDL.
We humans can obtain all the protein we need from the same source the animals raised for food obtain their protein: plants.
This eliminates the middle man. Plus, it provides the necessary amount of fiber and phytonutrients. It also prevents us from ingesting TMAO, LDL-c, saturated fat, heme iron…
This eliminates the middle man. Plus, it provides the necessary amount of fiber and phytonutrients. It also prevents us from ingesting TMAO, LDL-c, saturated fat, heme iron…
October 5, 2025 at 11:35 AM
We humans can obtain all the protein we need from the same source the animals raised for food obtain their protein: plants.
This eliminates the middle man. Plus, it provides the necessary amount of fiber and phytonutrients. It also prevents us from ingesting TMAO, LDL-c, saturated fat, heme iron…
This eliminates the middle man. Plus, it provides the necessary amount of fiber and phytonutrients. It also prevents us from ingesting TMAO, LDL-c, saturated fat, heme iron…
LDL-C下げてもLp(a)高値は心血管リスク - 日経メディカル
news.google.com/rss/articles/CBMigAFBVV95cUxNbXM0LUxMQ1RTY3ViQm5fRXc1UUxBOWtab3hNSjAyVzZSUkxncHZDeU1zOFRtY0ZNRWNsMGhFQ3lySG5kSG96OGRMemY5X2ZORUp2OXRISjExOGFob1JBdy1vUGpIdUsyeVBpOVc0QktVbU95SUVDNzJKOWw1MGI0Rw?oc=5
news.google.com/rss/articles/CBMigAFBVV95cUxNbXM0LUxMQ1RTY3ViQm5fRXc1UUxBOWtab3hNSjAyVzZSUkxncHZDeU1zOFRtY0ZNRWNsMGhFQ3lySG5kSG96OGRMemY5X2ZORUp2OXRISjExOGFob1JBdy1vUGpIdUsyeVBpOVc0QktVbU95SUVDNzJKOWw1MGI0Rw?oc=5
February 13, 2025 at 6:09 AM
Not sure how I can eat two tablespoons of psyllium husks daily, this is like eating woodgrains. So gross. It's honestly not worth the reduction in ldl-c and apob 😭 maybe I'll just eat more veggies
November 14, 2024 at 8:12 PM
Not sure how I can eat two tablespoons of psyllium husks daily, this is like eating woodgrains. So gross. It's honestly not worth the reduction in ldl-c and apob 😭 maybe I'll just eat more veggies
Adding ezetimibe to moderate-intensity statins could be a better approach to reach target LDL-C levels with less new-onset diabetes and intolerance than high high-intensity statin strategy. I think that is true for all statin doses in renal transplant recipients
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
LDL Cholesterol–Lowering Strategy in ASCVD
This systematic review and individual patient data meta-analysis investigates the association of an alternative low-density lipoprotein (LDL) strategy with differences in long-term efficacy and safety...
jamanetwork.com
November 24, 2024 at 4:59 PM
Adding ezetimibe to moderate-intensity statins could be a better approach to reach target LDL-C levels with less new-onset diabetes and intolerance than high high-intensity statin strategy. I think that is true for all statin doses in renal transplant recipients
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
ldl-c 30's to 50's
not linked to dementia
#lipidology #cvprev #cardiosky #ldl-c #lipids #cholesterol #lipoproteins
evidence.nejm.org/doi/full/10....
not linked to dementia
#lipidology #cvprev #cardiosky #ldl-c #lipids #cholesterol #lipoproteins
evidence.nejm.org/doi/full/10....
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Concerns persist regarding the cognitive safety of achieving very low levels of low-density lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the long-term cognitive effect...
evidence.nejm.org
December 27, 2024 at 3:21 PM
ldl-c 30's to 50's
not linked to dementia
#lipidology #cvprev #cardiosky #ldl-c #lipids #cholesterol #lipoproteins
evidence.nejm.org/doi/full/10....
not linked to dementia
#lipidology #cvprev #cardiosky #ldl-c #lipids #cholesterol #lipoproteins
evidence.nejm.org/doi/full/10....
1/
Is LDL-C lowering by CETP inhibitor cardioprotective?
Brief history
ACCELERATE (Evacetrapib), N=12092, F/U: 28m
Mean LDL 81; LDL⬇️37%, Lp(a)⬇️22%
PEP (MACE-5): 12.9% vs 12.8% HR 1.01, 0.91-1.11
Trial stopped early due to futility
x.com/mdavidsonmd/...
Is LDL-C lowering by CETP inhibitor cardioprotective?
Brief history
ACCELERATE (Evacetrapib), N=12092, F/U: 28m
Mean LDL 81; LDL⬇️37%, Lp(a)⬇️22%
PEP (MACE-5): 12.9% vs 12.8% HR 1.01, 0.91-1.11
Trial stopped early due to futility
x.com/mdavidsonmd/...
x.com
x.com
November 20, 2024 at 5:42 AM
1/
Is LDL-C lowering by CETP inhibitor cardioprotective?
Brief history
ACCELERATE (Evacetrapib), N=12092, F/U: 28m
Mean LDL 81; LDL⬇️37%, Lp(a)⬇️22%
PEP (MACE-5): 12.9% vs 12.8% HR 1.01, 0.91-1.11
Trial stopped early due to futility
x.com/mdavidsonmd/...
Is LDL-C lowering by CETP inhibitor cardioprotective?
Brief history
ACCELERATE (Evacetrapib), N=12092, F/U: 28m
Mean LDL 81; LDL⬇️37%, Lp(a)⬇️22%
PEP (MACE-5): 12.9% vs 12.8% HR 1.01, 0.91-1.11
Trial stopped early due to futility
x.com/mdavidsonmd/...
It’s used as add on to other lipid lowering therapy in known cardiovascular disease where LDL-C is at least 1.04mmol/l but less than 2.6mmol/l. I have used very little especially at £150/month compared to statins £2/month, Bempedoic Acid/Ezetimibe £55/month & Inclisiran £100/year (£8/month).
September 26, 2023 at 9:24 AM
It’s used as add on to other lipid lowering therapy in known cardiovascular disease where LDL-C is at least 1.04mmol/l but less than 2.6mmol/l. I have used very little especially at £150/month compared to statins £2/month, Bempedoic Acid/Ezetimibe £55/month & Inclisiran £100/year (£8/month).
Merck's enlicitide, an oral PCSK9i, meets LDL-C and other endpoints in 2 phase 3 trials. Details to come. "There were no clinically meaningful differences in incidences of AEs and SAEs in either trial" #cardiosky
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
June 9, 2025 at 1:03 PM
Merck's enlicitide, an oral PCSK9i, meets LDL-C and other endpoints in 2 phase 3 trials. Details to come. "There were no clinically meaningful differences in incidences of AEs and SAEs in either trial" #cardiosky
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
www.merck.com/news/merck-a...
bsky.app/profile/fipc...
$NAMS +1.8% [Citi started coverage of NewAmsterdam Pharma with a Buy and a price target of $42. The LDL cholesterol lowering market has a significant unmet need, with over 75% of patients requiring more therapies. "Obicetrapib aims to be a first-in-class add-on treatment for LDL-C levels."]
June 17, 2025 at 10:53 AM
$NAMS +1.8% [Citi started coverage of NewAmsterdam Pharma with a Buy and a price target of $42. The LDL cholesterol lowering market has a significant unmet need, with over 75% of patients requiring more therapies. "Obicetrapib aims to be a first-in-class add-on treatment for LDL-C levels."]
The results showed that the modified Sampson calculation demonstrated the best overall correlation with the reference method, particularly in patients with high triglycerides and low LDL-C levels.
October 8, 2025 at 10:07 PM
The results showed that the modified Sampson calculation demonstrated the best overall correlation with the reference method, particularly in patients with high triglycerides and low LDL-C levels.
This finding suggests that the modified Sampson formula should replace the Friedewald method and potentially direct LDL-C measurements when making clinical decisions for patients with these lipid profiles.
October 8, 2025 at 10:07 PM
This finding suggests that the modified Sampson formula should replace the Friedewald method and potentially direct LDL-C measurements when making clinical decisions for patients with these lipid profiles.
Resultados CONTROL+T: radiografía de la protocolización del control temprano del c-LDL en España
Sociedad Española de Cardiología
youtu.be/d-iBW-FX_eU?...
Sociedad Española de Cardiología
youtu.be/d-iBW-FX_eU?...
Resultados CONTROL+T: radiografía de la protocolización del control temprano del c-LDL en España
YouTube video by Sociedad Española de Cardiología
youtu.be
November 5, 2025 at 12:56 AM
Resultados CONTROL+T: radiografía de la protocolización del control temprano del c-LDL en España
Sociedad Española de Cardiología
youtu.be/d-iBW-FX_eU?...
Sociedad Española de Cardiología
youtu.be/d-iBW-FX_eU?...
脳梗塞既往患者のLDL-C目標値、より厳格にすべき？／Circulation｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
November 10, 2025 at 3:09 AM
脳梗塞既往患者のLDL-C目標値、より厳格にすべき？／Circulation｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
💬 Editorial: While early detection and treatment may help some high-risk youth, the study by Bellows et al suggests broader population approaches to lower LDL-C distribution may offer greater cost-effectiveness.
#AHA25 @ahascience.bsky.social
ja.ma/4hMcFD6
#AHA25 @ahascience.bsky.social
ja.ma/4hMcFD6
November 9, 2025 at 11:20 PM
💬 Editorial: While early detection and treatment may help some high-risk youth, the study by Bellows et al suggests broader population approaches to lower LDL-C distribution may offer greater cost-effectiveness.
#AHA25 @ahascience.bsky.social
ja.ma/4hMcFD6
#AHA25 @ahascience.bsky.social
ja.ma/4hMcFD6
脳梗塞既往患者のLDL-C目標値、より厳格にすべき？／Circulation｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
November 9, 2025 at 9:09 PM
脳梗塞既往患者のLDL-C目標値、より厳格にすべき？／Circulation｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
news.google.com/rss/articles/CBMiX0FVX3lxTFB1MnpSVl9qN3hKSFl1M25OcW84UDM2cDFKcU5UOVZ5XzI4UjdzZ0k5UmNLMzJESkx5aWJFUEN0UE5neHdkaE14YUFQazFKVFBkd2hOLVhZaVNJU1RST2dF?oc=5
. . . The authors found the most improvement over the first four weeks of the diet change. The participants with a vegan diet had significantly lower low-density lipoprotein cholesterol (LDL-C) levels, insulin and body weight —
December 25, 2024 at 8:41 PM
. . . The authors found the most improvement over the first four weeks of the diet change. The participants with a vegan diet had significantly lower low-density lipoprotein cholesterol (LDL-C) levels, insulin and body weight —
芭樂降膽固醇嗎？
芭樂富含膳食纖維，有助於降低膽固醇。研究顯示，攝取足夠的芭樂，能有效促進膽固醇排出體外，並降低血液中低密度脂蛋白膽固醇（LDL-C）的含量。 定期食用芭樂，搭配均衡飲食及適度運動，能有效提升心血管健康，預防心血管疾病。 選擇新鮮、成熟的芭樂，並適量食用，才能充分發揮其保健功效。
芭樂富含膳食纖維，有助於降低膽固醇。研究顯示，攝取足夠的芭樂，能有效促進膽固醇排出體外，並降低血液中低密度脂蛋白膽固醇（LDL-C）的含量。 定期食用芭樂，搭配均衡飲食及適度運動，能有效提升心血管健康，預防心血管疾病。 選擇新鮮、成熟的芭樂，並適量食用，才能充分發揮其保健功效。
芭樂降膽固醇嗎？
芭樂富含膳食纖維，有助於降低膽固醇。研究顯示，攝取足夠的芭樂，能有效促進膽固醇排出體外，並降低血液中低密度脂蛋白膽固醇（LDL-C）的含量。 定期食用芭樂，搭配均衡飲食及適度運動，能有效提升心血管健康，預防心血管疾病。 選擇新鮮、成熟的芭樂，並適量食用，才能充分發揮其保健功效。
www.isuperman.tw
January 3, 2025 at 12:05 AM
芭樂降膽固醇嗎？
芭樂富含膳食纖維，有助於降低膽固醇。研究顯示，攝取足夠的芭樂，能有效促進膽固醇排出體外，並降低血液中低密度脂蛋白膽固醇（LDL-C）的含量。 定期食用芭樂，搭配均衡飲食及適度運動，能有效提升心血管健康，預防心血管疾病。 選擇新鮮、成熟的芭樂，並適量食用，才能充分發揮其保健功效。
芭樂富含膳食纖維，有助於降低膽固醇。研究顯示，攝取足夠的芭樂，能有效促進膽固醇排出體外，並降低血液中低密度脂蛋白膽固醇（LDL-C）的含量。 定期食用芭樂，搭配均衡飲食及適度運動，能有效提升心血管健康，預防心血管疾病。 選擇新鮮、成熟的芭樂，並適量食用，才能充分發揮其保健功效。
The #FDA has accepted the BLA for @LIBTherapeutics lerodalcibep targeting reductions in LDL-C in populations at high cardiovascular risk. A PDUFA date of December 12, 2025 has been set, with no plans to hold an advisory committee meeting.
🔗
#Cardiology #FDANews
🔗
#Cardiology #FDANews
February 11, 2025 at 1:46 PM
The #FDA has accepted the BLA for @LIBTherapeutics lerodalcibep targeting reductions in LDL-C in populations at high cardiovascular risk. A PDUFA date of December 12, 2025 has been set, with no plans to hold an advisory committee meeting.
🔗
#Cardiology #FDANews
🔗
#Cardiology #FDANews
綾鷹うめ〜これでLDL-C下がる(？)のはデカい
November 13, 2024 at 2:40 AM
綾鷹うめ〜これでLDL-C下がる(？)のはデカい
Many followers report improved energy and weight loss, yet surveys show very high LDL cholesterol levels in users.
How could one get enough vitamin C, fiber, and antioxidants while staying mostly carnivore?
#beh353
@beh353.bsky.social
How could one get enough vitamin C, fiber, and antioxidants while staying mostly carnivore?
#beh353
@beh353.bsky.social
y.social
October 7, 2025 at 1:38 PM
Many followers report improved energy and weight loss, yet surveys show very high LDL cholesterol levels in users.
How could one get enough vitamin C, fiber, and antioxidants while staying mostly carnivore?
#beh353
@beh353.bsky.social
How could one get enough vitamin C, fiber, and antioxidants while staying mostly carnivore?
#beh353
@beh353.bsky.social
Bananas are both good sources of fiber, potassium, vitamin C, magnesium, vitamin B6 and manganese. Our gut bacteria love the fiber & resistant starch that bananas contain. Bananas have also been shown to reduce fasting blood sugar levels & lower the LDL to HDL ratio.
#nutrivore #nutrientdensefoods
#nutrivore #nutrientdensefoods
December 5, 2024 at 3:24 PM
Bananas are both good sources of fiber, potassium, vitamin C, magnesium, vitamin B6 and manganese. Our gut bacteria love the fiber & resistant starch that bananas contain. Bananas have also been shown to reduce fasting blood sugar levels & lower the LDL to HDL ratio.
#nutrivore #nutrientdensefoods
#nutrivore #nutrientdensefoods
Our human PCSK9-targeting epigenetic editor is fully cross-reactive against cyno PCSK9, & we demonstrated that a single administration led to rapid and sustained, 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates
7/9
7/9
February 10, 2025 at 2:05 PM
Our human PCSK9-targeting epigenetic editor is fully cross-reactive against cyno PCSK9, & we demonstrated that a single administration led to rapid and sustained, 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates
7/9
7/9